CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for ...

Novo Nordisk has announced that chief executive Lars Fruergaard Jørgensen will step down just days after the pioneering maker of obesity drugs cut its profit forecast. The Danish group said on Friday ...

Over Lars Fruergaard Jørgensen's eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company ...

When Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen dialed into a Teams video call with Chairman Helge ...

The International School of Kalundborg is set to open its doors in August 2025, and now receives a financial boost from the Novo Nordisk Foundation. The DKK 6.5 million donation will support the ...

It would be another two years before French researchers would identify a retrovirus as the cause of AIDS, or acquired immunodeficiency syndrome, according to the CDC. It would be another three years ...

Beyond 2 years, CABG with flow assessment was associated with a higher risk for new coronary angiography and new ...

Given Novo Nordisk’s history with diabetes, and its current association with weight loss drugs, it makes sense that cardiometabolic disease should be one of the main focuses of the Foundation ...

Modern HIV medicine is based on a common genetic mutation. Now, researchers have traced where and when the mutation arose -- and how it protected our ancestors from ancient diseases.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...